pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Apr 28·1 min read
save

Supreme Court to hear arguments on generic fish‑oil pill case, industry watches

Apr 28, 2026·read at Endpoints ↗RegulatoryNeutral

The U.S. Supreme Court is set to hear arguments this week on a case involving a prescription‑strength pill derived from fish oil.

The dispute centers on whether the product qualifies as a generic version of an existing drug, a question that could shape how new generics are evaluated and approved.

Industry observers say the outcome may have wide‑reaching effects on the generic market, prompting close attention from manufacturers and investors.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Hikma and Amarin's generic drug case heads to Supreme Court arguments”

read at Endpoints ↗
94 words · retrieved Apr 28
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
HIKMA
drugs
OMEGAVEN4

related stories

  • Jun 5Generic drugmakers gain key victory in ‘skinny label’ patent caseBioPharma Dive
  • Jun 4Supreme Court sides with Hikma in 'skinny label' caseEndpoints
  • Aug 13Opinion: How to disrupt the health misinformation business modelSTAT
  • Jul 13Building a workforce engine for biomanufacturingFierce Biotech
  • Jun 4STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ caseSTAT